7545-52-0

Basic information

• Product Name: Ethyl 6-chloro-4-oxo-1,4-dihydroquinoline-2-carboxylate
• Synonyms: Ethyl 6-chloro-4-oxo-1,4-dihydroquinoline-2-carboxylate;Methyl 6-chloro-4-oxo-1,4-dihydroquinoline-2-carboxylate;6-Chloro-4-oxo-1,4-dihydro-quinoline-2-carboxylic acid methyl ester
• CAS NO: 7545-52-0
• Molecular Formula: C12H10ClNO3
• Molecular Weight: 251.6657
• Mol File: 7545-52-0.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Ethyl 6-chloro-4-oxo-1,4-dihydroquinoline-2-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl 6-chloro-4-oxo-1,4-dihydroquinoline-2-carboxylate(7545-52-0)
• EPA Substance Registry System: Ethyl 6-chloro-4-oxo-1,4-dihydroquinoline-2-carboxylate(7545-52-0)

Safety Data

• Hazardous Substances Data: 7545-52-0(Hazardous Substances Data)

Usage

General Description

Ethyl 6-chloro-4-oxo-1,4-dihydroquinoline-2-carboxylate is a chemical compound with the molecular formula C14H13ClN2O3. It is a derivative of quinoline and belongs to the class of organic compounds known as quinolones. Ethyl 6-chloro-4-oxo-1,4-dihydroquinoline-2-carboxylate is often used in the pharmaceutical industry as a building block for the synthesis of various drugs and pharmaceutical products. It exhibits antimicrobial and antibacterial properties, making it valuable for the development of antibiotics. Additionally, it has been studied for its potential anticancer and antimalarial activities. Ethyl 6-chloro-4-oxo-1,4-dihydroquinoline-2-carboxylate is typically synthesized through organic chemical reactions and is marketed for research and industrial purposes.

Upstream product

• 106-47-8 4-chloro-aniline 
• 762-42-5 dimethyl acetylenedicarboxylate 
• 87748-34-3 C₁₂H₁₂ClNO₄ 

Downstream Products

• 24796-59-6 6-chloro-4-oxo-1,4-dihydroquinoline-2-carboxylic acid 

Relevant articles and documents

Design, synthesis, and biological evaluation of novel arylcarboxamide derivatives as anti-tubercular agents

Our group has previously reported several indolecarboxamides exhibiting potent antitubercular activity. Herein, we rationally designed several arylcarboxamides based on our previously reported homology model and the recently published crystal structure of the mycobacterial membrane protein large 3 (MmpL3). Many analogues showed considerable anti-TB activity against drug-sensitive (DS) Mycobacterium tuberculosis (M. tb) strain. Naphthamide derivatives 13c and 13d were the most active compounds in our study (MIC: 6.55, 7.11 μM, respectively), showing comparable potency to the first line anti-tuberculosis (anti-TB) drug ethambutol (MIC: 4.89 μM). In addition to the naphthamide derivatives, we also identified the quinolone-2-carboxamides and 4-arylthiazole-2-carboxamides as potential MmpL3 inhibitors in which compounds 8i and 18b had MIC values of 9.97 and 9.82 μM, respectively. All four compounds retained their high activity against multidrug-resistant (MDR) and extensively drug-resistant (XDR) M. tb strains. It is worth noting that the two most active compounds 13c and 13d also exhibited the highest selective activity towards DS, MDR and XDR M. tb strains over mammalian cells [IC50 (Vero cells) ≥ 227 μM], indicating their potential lack of cytotoxicity. The four compounds were docked into the MmpL3 active site and were studied for their drug-likeness using Lipinski's rule of five.

DIAMINE DERIVATIVES

A compound represented by formula (1):Q1-Q2-To-N(R1) -Q3-N(R2)-T1-Q4 [wherein R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6- membered cyclic hydrocarbon group which may be substituted, or the like; Q2 is a single bond or the like; Q3 represents the following group: (wherein Q5 is an alkylene group having 1 to 8 carbon atoms, or the like); and T0 and T1 are carbonyl groups or the like], a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after artificial valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

DIAMINE DERIVATIVES

A compound represented by the general formula (1):Q1-Q2-T0-N(R1)-Q3-N(R2)-T1-Q4 wherein R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6- membered cyclic hydrocarbon group which may be substituted, or the like; Q2 is a single bond or the like; Q3 is a group in which Q5 is an alkylene group having 1 to 8 carbon atoms, or the like; and T0 and T1 are carbonyl groups or the like; a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.